<DOC>
	<DOCNO>NCT02052544</DOCNO>
	<brief_summary>To demonstrate substantial equivalence ( SE ) Pefakit® PiCT® UC ( test device , T ) aPTT-SP ( Hemosil ) ( predicate device , P ) determine heparin level subject undergoing heparin therapy support United States Food Drug Administration ( FDA ) 510 ( k ) submission .</brief_summary>
	<brief_title>Clinical Performance Evaluation Pefakit® PiCT® UC In Vitro Diagnostic Medical Device</brief_title>
	<detailed_description>Standard Care Study . Objective monitor patient ' heparin level treatment continuous unfractionated heparin infusion . Blood sample collection ( 4 ml ) require routinely . A proportion standard sample ( leftover plasma ) use study purpose . About three sample analyze collect within 2 - 4 day . Time point blood sample collection define treat physician accord local standard care associate exclusively clinical consideration . Results Pefakit® PiCT® UC assay NOT use take therapeutic decision study subject .</detailed_description>
	<mesh_term>Thromboembolism</mesh_term>
	<criteria>Subjects receive continuous infusion UFH Subjects give write informed consent ( unless write informed consent waive local regulation local EC/IRB ) Subjects treated anticoagulant UFH Subjects undergoing fibrinolytic therapy within previous 4 week Subjects know congenital bleeding disorder Subjects know present unexplained prolongation clot time Subjects know coagulation factor deficiency Patient participate participate within one month enrolment another investigational study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>determination heparin level</keyword>
	<keyword>Patients</keyword>
	<keyword>require</keyword>
	<keyword>unfractionated</keyword>
</DOC>